Dosing — 2026-05-07
Of all the questions researchers ask about reta, dosing comes up the most. The triple agonist is the most potent metabolic peptide ever brought into late-stage clinical trials, and that potency cuts both ways — too aggressive a titration produces severe GI adverse events, while underdosing simply doesn't replicate the published outcomes. This guide summarizes what the Phase 2 data tells us about how reta is dosed in research settings.
Researcher special — code WELCOME unlocks 35% off all reta vials and the Metabolic and Shredder Stacks at checkout. If you're sourcing material for a titration study, this is the point in the protocol where lab-grade purity and consistent batch-to-batch potency matter most — Platinum Biolabs ships every vial with a batch-matched COA showing 99%+ HPLC purity.
The pivotal Phase 2 obesity trial (Jastreboff et al., NEJM 2023) used a starting dose of 2 mg once weekly across all dose arms. This is well below the eventual target dose, and exists specifically to let the gut adapt to GP-1 receptor activation before adding the GIP and glucagon receptor effects on top.
The Phase 2 type 2 diabetes trial (Rosenstock et al., Lancet 2023) used the same 2 mg starting point.
In both trials, this starting week is considered an "induction" dose, not a therapeutic dose. Expect minimal weight or glycemic effect during the first 2-4 weeks of any protocol modeled on these schedules.
The published trials used monthly (4-weekly) titration steps. The escalation logic was:
The most aggressive trial schedule reached 12 mg by week 21. Some research protocols extend the spacing to 6 or 8 weeks per step to further reduce GI burden, particularly in non-trial populations who lack the support infrastructure of a clinical trial.
The dominant adverse events in reta research are GI: nausea, diarrhea, vomiting, and decreased appetite. These are dose-dependent and concentrate during dose escalation, not maintenance. Trial data consistently shows:
This is the single most important practical point for any research protocol: the titration schedule is the protocol. Jumping from 2 mg to 8 mg without intermediate steps is not a reasonable interpretation of the published data.
Reta is supplied lyophilized. Most researchers reconstitute a 10 mg vial with 2 mL of bacteriostatic water, yielding 5 mg/mL. At that concentration:
| Target dose | Volume per dose |
| 2 mg | 0.4 mL (40 units on a U-100 syringe) |
| 4 mg | 0.8 mL (80 units) |
| 6 mg | 1.2 mL (120 units, may need to split) |
| 8 mg | 1.6 mL (split into two injections) |
| 12 mg | 2.4 mL (split) |
For the 20 mg vial, the same math doubles. Many researchers reconstitute the 20 mg vial with 4 mL to keep the same 5 mg/mL concentration and simpler unit conversion.
All Phase 2 reta trials used once-weekly subcutaneous administration. The peptide's albumin-binding fatty acid chain gives it a half-life of approximately 6 days, which makes weekly dosing the natural fit for steady-state exposure. There is no published evidence supporting more frequent dosing, and no published evidence that less-than-weekly dosing produces equivalent outcomes.
A practical pattern that has emerged in research protocols: not every researcher is targeting 12 mg. The dose-response curve is flat-ish at the top end — the 8 mg arm in the Phase 2 trial produced approximately 22% body weight reduction at 48 weeks, not far below the 24% at 12 mg. The 4 mg arm produced approximately 17%.
If GI tolerability is poor at 8 mg, holding rather than escalating produces near-maximum effect with much better quality of life. This is increasingly how research protocols are designed: titrate to the highest dose that's well-tolerated, not necessarily to the highest dose studied.
Reta dosing is fundamentally a titration problem. The published outcomes are achievable, but only with a protocol that respects the GI tolerability window. Aggressive dosing produces dropouts, not faster results. The Phase 2 monthly-step schedule is the well-validated baseline; many researchers extend the spacing further with no apparent loss of efficacy.
When you're ready to source material for a titration study, use code WELCOME at checkout for 35% off reta vials, the Metabolic Stack (Reta + Tesa), and the Shredder Stack (Reta + Tesa + MOTS-C). Every vial includes a batch-matched COA, ships from a US facility, and arrives ready for reconstitution.
Disclaimer: All information presented in this article is for educational and informational purposes only. Platinum Biolabs does not promote or endorse the use of peptides for human consumption. All products sold by Platinum Biolabs are intended strictly for laboratory and research use only. Consult a qualified healthcare professional before making any health-related decisions.